Clinical Trial Update: Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue [Phase 3]

View source ↗

Summary

Phase 3 study of GSK548470 in patients with compensated chronic hepatitis B who had not been treated with nucleoside/nucleotide analogue therapy has completed; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• GSK548470

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B, Chronic | Phase 3 | Status: COMPLETED | Results posted: 2013-10-29